This report was first published by Endpoints News. To see the original version, click here
Areteia Therapeutics, one of the biotech industry’s biggest recent startup bets in respiratory illness, has decided to wind down, according to a source familiar with the decision.
The company’s top executives appear to have left, and the startup also terminated three trials from its broad Phase 3 program, according to a US trials database.
您已阅读19%（430字），剩余81%（1811字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。